PT  - JOURNAL ARTICLE
AU  - Overwijk, Willem W
AU  - Wang, Ena
AU  - Marincola, Francesco M
AU  - Rammensee, Hans-Georg
AU  - Restifo, Nicholas P
AU - for the Organizing Committee of the 2013 SITC Workshop on Personalized Immunotherapy
TI  - Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors
AID  - 10.1186/2051-1426-1-11
DP  - 2013 Dec 01
TA  - Journal for ImmunoTherapy of Cancer
PG  - 11
VI  - 1
IP  - 1
4099  - http://jitc.bmj.com/content/1/1/11.short
4100  - http://jitc.bmj.com/content/1/1/11.full
SO  - J Immunother Cancer2013 Dec 01; 1
AB  - T cells can mediate remarkable tumor regressions including complete cure in patients with metastatic cancer. Genetic alterations in an individual’s cancer cells (the mutanome) encode unique peptides (m-peptides) that can be targets for T cells. The recent advances in next-generation sequencing and computation prediction allows, for the first time, the rapid and affordable identification of m-peptides in individual patients. Despite excitement about the extended spectrum of potential targets in personalized immunotherapy, there is no experience or consensus on the path to their successful clinical application. Major questions remain, such as whether clinical responses to cytokine therapy, T cell transfer, and checkpoint blockade are primarily mediated by m-peptide-specific reactivity, whether m-peptides can be effectively used as vaccines, and which m-peptides are most potently recognized. These and other technological, immunological and translational questions will be explored during a 1-day Workshop on Personalized Cancer Immunotherapy by the Society for Immunotherapy of Cancer, directly before the Annual Meeting, on November 7, 2013 at the National Harbor, MD near Washington, DC.Abbreviations:TILTumor-infiltrating lymphocytesPBMCPeripheral blood mononuclear cellsTCRT cell receptorMHCMajor histocompatibility complexHLAHuman leukocyte antigen.